The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.
A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit
Open accessAbstract
The structure of the catalytic subunit of cAMP-dependent protein kinase (PKA-C), a prototype for the protein kinase superfamily, laid the foundation for the development of targeted kinase inhibitors. Here we describe the structure and biophysical characterization of a PKA-C complex with BLU0588, a small PKA-selective inhibitor. The high-resolution crystal structure not only captures the inhibitor’s unusual T-shaped geometry, but also shows how the four rings of BLU0588 serve as surrogates for ATP’s adenosine and phosphate-organizing sites. Each site contains two subsites. BLU0588’s planar azaindole and pyridine rings, which are buried beneath the glycine-rich loop in a hydrophobic shell at the base of the active site cleft, fill the adenine and ribose subsites. In contrast, BLU0588’s indane and pyrrolidine rings fill the phosphate-organizing site. The indane ring occupies the α/β-phosphate organizing site while the pyrrolidine ring fills the Mg/γ-phosphate organizing site. The structure also shows how BLU0588 nucleates an open but stable conformation of the entire hydrophobic architecture of the N- and C-lobes. In addition to potently blocking phosphoryl transfer activity, BLU0588 also abolishes the synergistic high-affinity binding of the physiological pseudosubstrate inhibitor, protein kinase inhibitor. The residence time of BLU0588, measured by surface plasmon residence, contributes to its picomolar affinity and is distinct from H89, a commonly used but more promiscuous PKA inhibitor. These molecular insights provide a valuable framework for dissecting the organization of the active site cleft as well as different strategies for the rational design of more potent and selective kinase inhibitors in general.
Overview
CoChat Summary
TL;DR
BLU0588 is a PKA-selective ATP-competitive inhibitor that binds PKA-C with picomolar affinity, stabilizes an open but more ordered kinase conformation, and abolishes synergistic high-affinity binding of the pseudosubstrate PKI peptide IP20. A 1.55 Å crystal structure shows its four hydrophobic rings occupy the entire ATP-binding cleft, replacing both adenosine and phosphate/Mg²⁺-organizing subsites.
Key findings
- The 1.55 Å PKA-C:IP20:BLU0588 structure shows BLU0588 buried under the glycine-rich loop: azaindole/pyridine rings occupy the adenine/ribose subsites, while indane/pyrrolidine rings occupy the phosphate/Mg²⁺ subsites. The G-loop is shifted upward in an open but ordered conformation, disrupting the Phe54–Phe187 interaction and the His87–pThr197 hydrogen bond; DFG and αC-helix salt bridge are “in,” classifying BLU0588 as a Type 1 inhibitor.
- BLU0588 abolishes IP20/PKI binding synergy: ITC gave Kd 3.8 µM for PKI binding to apo PKA-C versus 2.9 µM for BLU0588-bound PKA-C, with cooperativity coefficient σ ≈ 1.3; FP showed no FAM-IP20 binding in the presence of BLU0588. BLU0588 increased Tm from 42.7 ± 0.9 °C to 57.0 ± 0.7 °C (ΔTm ~14 °C), whereas IP20 alone enhanced thermostability by only ~3 °C and AMP-PNP by only ~2 °C (Tm = 44.6 ± 0.8 °C).
- BLU0588 is potent and slow-off: apparent Ki = 230 ± 10 pM; SPR gave kass = 26 × 10⁶ M⁻¹s⁻¹ ± 1.8 × 10⁶ M⁻¹s⁻¹, kdiss = 5.6 × 10⁻³ s⁻¹ ± 0.7 × 10⁻³ s⁻¹, KD = 0.21 ± 0.01 nM, with 1:1 stoichiometry. Compared with H89, BLU0588 had an 11-fold slower off-rate, 3.2-fold slower on-rate, and 35-fold higher affinity; H89 SPR gave kass = 8.3 × 10⁶ M⁻¹s⁻¹ ± 0.3 × 10⁶ M⁻¹s⁻¹, kdiss = 60 × 10⁻³ s⁻¹ ± 6.4 × 10⁻³ s⁻¹, KD = 7.3 ± 1.1 nM, and H89 increased Tm by ~11 °C versus ~14 °C for BLU0588.
- BLU0588 nucleates an extended hydrophobic network: the C-tail is ordered, with FDDY residues Phe327 and Tyr330 surrounding the azaindole; the C-spine is preserved, the R-spine is assembled with small shifts, and five highly coordinated waters occupy the active site.
Methods
- X-ray crystallography: PKA-C:IP20:BLU0588 complex solved to 1.55 Å in space group P212121 (a = 69.5 Å, b = 73.1 Å, c = 76.5 Å), by molecular replacement using PDB ID 1ATP as search model; refinement yielded R-work 0.18 and R-free 0.21.
- Biophysical and biochemical assays: differential scanning fluorimetry for thermal stability; isothermal titration calorimetry for PKI(5-24) binding; fluorescence polarization with FAM-IP20; coupled spectrophotometric kinase assay with Kemptide and global Morrison equation fit for apparent Ki; surface plasmon resonance with FSS-tagged human PKA-Cα for BLU0588 and H89 kinetics.
- Samples: murine or human full-length wild-type PKA-Cα expressed in E. coli for crystallization, FP, and DSF; N-terminally FSS-tagged human PKA-Cα expressed in E. coli for Ki determination and SPR.
Limitations
- Stated in the paper: SPR interactions were strongly influenced by mass transfer limitation; including 5 mM ATP lowered the fit R² to <0.981, suggesting additional effects at high ATP not explained by simple competition; the authors state their goal is not to explain BLU0588 selectivity or design more selective inhibitors; additional kinetic, NMR, MD, SPR, and crystallography experiments are described as underway.
- Evident from the text: the prediction that BLU0588 hinders RIα binding was not directly tested; the study is structural and in vitro, with no cellular or in vivo efficacy data; the H89 comparison uses prior structural data (PDB ID 1YDT) and SPR data described as a representative experiment of n = 2 experimental setups.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5. Biochemical analysis of BLU0588 binding to PKA-C. (A) B-factor comparison of the kinase core between BLU0588-bound (Left) and ATP-bound (Right) PKA-C. B-factors of the color bar scale range from 20 to 100 for the ATP-bound structure and from 10 to 70 for the BLU0588-bound structure. (B) Thermal denaturation profile of PKA-C in the absence (black) and in the presence of BLU0588 (blue). Three different ratios of PKA-C:IP20 [1:10 (pink), 1:20 (orange), and 1:50 (red)] were tested. (C) Histogram representing the Tm (°C) values of PKA-C apo (42 ± 1), with 50 µM BLU0588 (56 ± 1), and at three different molar ratios of PKA-C:IP20, 1:10 (57 ± 1), 1:20 (57 ± 1), and 1:50 (58 ± 2). (D) Determination of the apparent Ki for BLU0588. Phosphorylation of the peptide substrate Kemptide was inhibited by adding BLU0588 with various ATP concentrations as indicated in the legend. Enzyme activities with inhibitor concentrations below 1 µM are enlarged in the inlet (gray background). The apparent Ki was calculated using global fit of the Morrison equation for tight binding inhibitors (see methods). Data fitted globally for 50 µM, 100 µM, 500 µM, and 1 mM ATP yielded an R2 > 0.993; including 5 mM ATP lowered the R2-value to R2 < 0.981, suggesting additional effects at high ATP not explained by a simple competition with ATP/Mg2+. (E) FP assay to analyze the binding of fluorescein-labeled IP20 peptide to PKA-C (0.25 to 512 nM) in buffer containing 10 mM MgCl2 in the presence (●) or absence (■) of 1 mM ATP. Each experiment was tested in triplicate and the data were analyzed with GraphPad Prism9.](/paper-figures/0d3c3d855527433c9410d7a0ba07d7a9/a-pka-selective-inhibitor-captures-an-open-but-more-ordered-conformation-of-the-figure-5.jpg)


Verification
Claims the paper makes
0 Valid · 0 Not valid · 24 Not checked · 116 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In summary, our data show that H89 binds PKA-C with a significantly lower affinity and does not stabilize the inhibited state as effectively as BLU0588.”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Unique Features of the BLU0588:PKA-C Interactions Compared to H89.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From these values we obtained a cooperativity coefficient (σ=(Kd^apo)/(Kd^BLU0588)) of ~1.3, indicating the absence of binding synergy between BLU0588 and the PKI peptide.”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Binding of BLU0588 Stabilizes the Conformation of PKA-C and Abolishes the Synergistic High-Affinity Binding of IP20.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we solved a crystal structure of a PKA-C:IP20:BLU0588 complex to 1.55 Å resolution (SI Appendix, Table S3).”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Structure of the C-Subunit in Complex with BLU0588 and IP20.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interactions of Asp184 with the catalytic machinery in the C-lobe are completely severed by BLU0588.”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > BLU0588 Abolishes the Electrostatic Interactions Associated with the Phosphates of ATP.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In summary, our data show that H89 binds PKA-C with a significantly lower affinity and does not stabilize the inhibited state as effectively as BLU0588.”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Unique Features of the BLU0588:PKA-C Interactions Compared to H89.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
77 more claims
Create a free account to see all 140 claims and to verify the 39 references still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 17
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Binding of BLU0588 Stabilizes the Conformation of PKA-C and Abolishes the Synergistic High-Affinity Binding of IP20.
“(D) Determination of the apparent Ki for BLU0588.”
§ A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit > Results > Binding of BLU0588 Stabilizes the Conformation of PKA-C and Abolishes the Synergistic High-Affinity Binding of IP20.
“The resulting apparent inhibitory constant (Ki) of BLU0588 was determined to be 230 ± 10 pM (Fig. 5E)”
Citations
Cites
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Rapid measurement of binding constants and heats of binding using a new titration calorimeter
Wiseman, T., Williston, S., Brandts, J. F., & Lin, L.-N. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90213-3 · Cited by 2,675
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
Self-citationChemical and biological evolution of a nucleotide-binding protein
Rossmann, M. G., Moras, D., & Olsen, K. W. (1974) · Nature · doi:10.1038/250194a0 · Cited by 1,469
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Walsh, D. A., Ashby, C. D., Gonzalez, C., Calkins, D., Fischer, E. H., & Krebs, E. G. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77177-4 · Cited by 887
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Research works printed but not linked: 3
- B. E. Kemp, Peptides and Protein Phosphorylation (CRC Press, 1990).
- 10.7554/elife.91506.3 · doi:10.7554/elife.91506.3
- 10.1124/mol.56.2.370 · doi:10.1124/mol.56.2.370
Cited by
Suarez, A. I., Chávez, K. E., Martínez, P., Bubis, J. J., Blanco, Z., Ramírez, H., Garmendia, J. V., Sanctis, J. B. D., Gurská, S., Džubák, P., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70425 · Cited by 1
Hagedorn, G. A., Spieser, J., Hirai, N., Sato, Y., Valentine, J., Jiang, H., Wang, W., Czyzyk-Krzeska, M., & Patra, K. C. (2026) · Science Advances · doi:10.1126/sciadv.aeh7186
A reversible GNAS-PKA-RUNX2 checkpoint governs skeletal stem cell fate in fibrous dysplasiaPreprint
Cárdenas, S., Rodriguez, D., Solis, A., Sato, K., Ishikawa, T., Adame-Garcia, S. R., Ochiai, T., Köckenberger, J., Shin, S. H., Du, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.02.756293
Self-citation
Metadata
- Authors
- Bruystens, J. G. H., Wu, J., Tan, G., Bertinetti, D., Zenn, H.-M., Zimmermann, B., Chen, L., Köckenberger, J., Massaro, F., Sankaran, B., Walters, M. S., Veglia, G., Ferguson, F. M., Herberg, F. W., & Taylor, S. S.
- Affiliations
- University of California San Diego (US)
- University of Kassel (DE)
- Biaffin (Germany) (DE)
- University of Minnesota (US)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Taylor, Susan S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2026-05-07
- Volume
- 123
- Issue
- 19
- Pages
- e2536312123-e2536312123
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC13167742
- OpenAlex
- W7160539317
- Semantic Scholar
- 5cf3c0a6087ed6f12cb3afaa1df1c1b614ff9b52
- Cited by
- 3
- References
- 64
- Citations by year
- 2026: 3
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- HHS | NIH | NIH Office of the Director (T32CA009523, GM130389, CA290129, GM124169)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- protein kinase A, PKA catalytic subunit, ATP-competitive inhibition, active site cleft, glycine-rich loop, phosphoryl transfer, residence time, H89
- MeSH terms
- Models, Molecular, Protein Conformation, Cyclic AMP-Dependent Protein Kinases, Crystallography, X-Ray, Catalytic Domain, Protein Kinase Inhibitors, Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit. https://app.cochat.ai/papers/10.1073/pnas.2536312123
- The paper
- Bruystens, J. G. H., Wu, J., Tan, G., Bertinetti, D., Zenn, H.-M., Zimmermann, B., Chen, L., Köckenberger, J., Massaro, F., Sankaran, B., Walters, M. S., Veglia, G., Ferguson, F. M., Herberg, F. W., & Taylor, S. S. (2026). A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2536312123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.